WEBULL
WebtradeDownload

CareDx (CDNA) Draws Momentum Interest, Is The Valuation Case Still Clear?

Simply Wall St · 1d ago

CareDx momentum signals draw fresh investor attention

Recent analyst commentary on CareDx (CDNA) has focused on its momentum characteristics, including a Momentum Style Score of B and a strong Zacks Rank, along with upward revisions to earnings estimates.

CareDx has attracted attention after a sharp run in the share price, with a 30 day share price return of 46.46% and a 90 day share price return of 129.45%. The 1 year total shareholder return of 299.39% suggests momentum has been building rather than fading, despite a weaker 5 year total shareholder return that is down 32.11%.

Spot fresh momentum stories like CareDx by reviewing our hand picked 20 high quality undiscovered gems that are starting to attract renewed interest from the market.

For CareDx, this surge could signal growing confidence in the transplant testing business, or simply hotter sentiment after strong recent returns. To separate story from mood, the valuation picture is the next step.

Most popular CareDx narrative: 10% overvalued

The most followed CareDx narrative lines up its fair value at $52.33 against the last close of $52.36, implying the stock trades slightly above that framework while still sitting very close to the narrative target.

The launch of AI-driven diagnostics like AlloSure Plus and integration into electronic health record systems (e.g., EPIC), positions CareDx to benefit from the broader adoption of precision medicine and personalized diagnostics, likely boosting adoption rates, aiding reimbursement, and ultimately supporting net margin improvements.

Read the complete narrative. Read the complete narrative.

To understand why this CareDx view supports a much richer earnings multiple ahead, the narrative focuses on rising test volumes, slimmer margins, and a punchy profit valuation to make the numbers stack up.

Result: Fair Value of $52.33 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in CareDx still need to watch for Medicare reimbursement changes and any execution missteps around Naveris integration, as these could quickly weaken this upbeat narrative.

Find out about the key risks to this CareDx narrative.

Another view on CareDx valuation

While the most followed CareDx narrative frames the stock as about 10% overvalued versus a $52.33 fair value, the SWS DCF model points in the other direction. At a last close of $52.36 and an estimated future cash flow value of $425.63, it flags a very large implied upside and a very different risk picture for investors to weigh.

Look into how the SWS DCF model arrives at its fair value.

CDNA Discounted Cash Flow as at Aug 2026
CDNA Discounted Cash Flow as at Aug 2026

Next Steps

With sentiment on CareDx split between risks and rewards, consider moving quickly, reviewing the underlying data, and weighing both sides for yourself. To help frame that decision, check the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond CareDx?

Do not stop with CareDx. The real edge often comes from scanning a wider watchlist, comparing different stories, and spotting patterns across sectors before everyone else.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.